Translate AMICOR contents if you like

Showing posts with label hypertension. Show all posts
Showing posts with label hypertension. Show all posts

Tuesday, May 26, 2020

Medication Reduction: Age 80 years and older

Key Points
Question  Among older adults taking multiple antihypertensive medications, is a strategy of antihypertensive medication reduction noninferior to usual care with regard to short-term blood pressure control?
Findings  In this randomized clinical trial that included 569 patients aged 80 years and older, the proportion with systolic blood pressure lower than 150 mm Hg at 12 weeks was 86.4% in the intervention group and 87.7% in the control group (adjusted relative risk, 0.98), a difference that met the noninferiority margin of a relative risk of 0.90.
Meaning  The findings suggest antihypertensive medication reduction can be achieved without substantial change in blood pressure control in some older patients with hypertension.
Abstract

Friday, March 27, 2020

BP Sex Differences

Key Points
Question  How do patterns of blood pressure (BP) change over the life course and differ between sexes?
Findings  In this analysis of 4 community cohort studies, trajectories of BP elevation in 32 833 individuals (54% women) were examined serially over 4 decades (age span, 5 to 98 years). Women compared with men exhibited a steeper increase in BP measures that began as early as in the third decade and continued throughout the life course.
Meaning  Sex differences in BP trajectories, which begin early and persist with aging, may set the stage for later-life cardiovascular diseases that frequently present differently in women vs men.
Abstract
Importance  If we assume that women and men exhibit variations of the same fundamental vascular physiology, then conventional analyses of subclinical measures would suggest that women catch up to men by midlife in the extent of potentially important vascular disease. Alternatively, under the assumption that vascular physiology may fundamentally differ between women and men, a sex-specific analysis of existing data could offer new insights and augment our understanding of sex differences in cardiovascular diseases.
Objective  To evaluate whether longitudinal patterns of blood pressure (BP) elevation differ between women and men during the life course when considering baseline BP levels as the reference.

Wednesday, November 27, 2019

On Recomendations for Hypertension


Views 2,516 
 
 
 

Key Points Español  ä¸­æ–‡ (Chinese)
Question  How consistent are recommendations from clinical practice guidelines regarding the diagnosis and management of hypertension?
........................
Conclusions and Relevance  Hypertension is a common chronic condition with widespread expectations surrounding guideline-based care, yet CPGs have a high rate of inconsistency. Further investigations should determine the reasons for inconsistency, the implications for recommendation development, and the role of synthesis across recommendations for optimal guidance of clinical care./.../

Friday, November 15, 2019

first-line antihypertensive

Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis

Using 4·9 million patients, we generated 22 000 calibrated, propensity-score-adjusted hazard ratios (HRs) comparing all classes and outcomes across databases. Most estimates revealed no effectiveness differences between classes; however, Thiazide or thiazide-like diuretics showed better primary effectiveness than angiotensin-converting enzyme inhibitors: acute myocardial infarction (HR 0·84, 95% CI 0·75–0·95), hospitalisation for heart failure (0·83, 0·74–0·95), and stroke (0·83, 0·74–0·95) risk while on initial treatment. Safety profiles also favoured thiazide or thiazide-like diuretics over angiotensin-converting enzyme inhibitors. The non-dihydropyridine calcium channel blockers were significantly inferior to the other four classes./.../

Thursday, August 29, 2019

Cuff-free BP Monitors

FDA Clears First Cuff-Free Blood Pressure Monitors

FDA Clears First Cuff-Free Blood Pressure Monitors
Categories: Cardiology, Geriatrics, Medicine, Sports Medicine
The FDA has granted Biobeat, an Israeli firm, clearance for the company's wrist watch and patch that measure blood oxygenation, heart rate, and blood pressure. Not relying on a traditional cuff allows for long-term monitoring of blood pressure, particularly in patients who have difficulty keeping track of their health parameters on their own. Moreover, it can help to identify abnormal …
Read more...

Saturday, August 17, 2019

Office x Ambulatory BP

Key Points
Question  What is the association of office and ambulatory blood pressure with subsequent risk of mortality and cardiovascular outcomes?
Findings  In a population-based cohort of 11 135 adults, higher 24-hour and nighttime blood pressure readings were significantly associated with greater risks of death and cardiovascular events that included cardiovascular mortality combined with nonfatal coronary events, heart failure, or stroke. This association persisted after adjusting for other blood pressure measurements taken during an office visit or during ambulatory monitoring.
Meaning  Higher 24-hour and nighttime blood pressure readings were significantly associated with greater risks of death and a composite of cardiovascular outcomes, although statistically the incremental model improvement was small.

Abstract
Importance  Blood pressure (BP) is a known risk factor for overall mortality and cardiovascular (CV)-specific fatal and nonfatal outcomes. It is uncertain which BP index is most strongly associated with these outcomes.
Objective  To evaluate the association of BP indexes with death and a composite CV event.
Design, Setting, and Participants  Longitudinal population-based cohort study of 11 135 adults from Europe, Asia, and South America with baseline observations collected from May 1988 to May 2010 (last follow-ups, August 2006-October 2016).
Exposures  Blood pressure measured by an observer or an automated office machine; measured for 24 hours, during the day or the night; and the dipping ratio (nighttime divided by daytime readings).
Main Outcomes and Measures  Multivariable-adjusted hazard ratios (HRs) expressed the risk of death or a CV event associated with BP increments of 20/10 mm Hg. Cardiovascular events included CV mortality combined with nonfatal coronary events, heart failure, and stroke. Improvement in model performance was assessed by the change in the area under the curve (AUC).
Results  Among 11 135 participants (median age, 54.7 years, 49.3% women), 2836 participants died (18.5 per 1000 person-years) and 2049 (13.4 per 1000 person-years) experienced a CV event over a median of 13.8 years of follow-up. Both end points were significantly associated with all single systolic BP indexes (P < .001). For nighttime systolic BP level, the HR for total mortality was 1.23 (95% CI, 1.17-1.28) and for CV events, 1.36 (95% CI, 1.30-1.43). For the 24-hour systolic BP level, the HR for total mortality was 1.22 (95% CI, 1.16-1.28) and for CV events, 1.45 (95% CI, 1.37-1.54). With adjustment for any of the other systolic BP indexes, the associations of nighttime and 24-hour systolic BP with the primary outcomes remained statistically significant (HRs ranging from 1.17 [95% CI, 1.10-1.25] to 1.87 [95% CI, 1.62-2.16]). Base models that included single systolic BP indexes yielded an AUC of 0.83 for mortality and 0.84 for the CV outcomes. Adding 24-hour or nighttime systolic BP to base models that included other BP indexes resulted in incremental improvements in the AUC of 0.0013 to 0.0027 for mortality and 0.0031 to 0.0075 for the composite CV outcome. Adding any systolic BP index to models already including nighttime or 24-hour systolic BP did not significantly improve model performance. These findings were consistent for diastolic BP.
Conclusions and Relevance  In this population-based cohort study, higher 24-hour and nighttime blood pressure measurements were significantly associated with greater risks of death and a composite CV outcome, even after adjusting for other office-based or ambulatory blood pressure measurements. Thus, 24-hour and nighttime blood pressure may be considered optimal measurements for estimating CV risk, although statistically, model improvement compared with other blood pressure indexes was small.

Monday, June 24, 2019

AD and BP

Blood Pressure Reduction and Alzheimer's Disease

-Study examines nilvadipine and cerebral blood flow, showing increased, safe flow to hippocampus

CME Author: Vicki Brower
Study Authors: Daan L. K. de Jong, Rianne A. A. de Heus, et al.
Target Audience and Goal Statement:
Neurologists, geriatricians, cardiologists, internists, family medicine specialists
The goal of this study was to determine whether blood pressure reduction with antihypertensive medication could affect cerebral blood flow, in particular, to the hippocampus and posterior cingulate cortex, in patients with Alzheimer clinical syndrome in a mild-to-moderate stage of dementia.
Questions Addressed:
  • Can the calcium channel blocker nilvadipine increase cerebral blood flow (CBF) in patients with mild-to-moderate Alzheimer's disease (AD)?
  • What parts of the brain are affected by lowering of blood pressure?
  • What effect does this have on cerebral autoregulation?

Action Points

Saturday, May 18, 2019

Blood Pressure Management

Guidelines for Management of High Blood Pressure in Adults

In 2014, panel members of the Eighth Joint National Committee published the results of their evidence review and deliberations about the prevention, detection, evaluation, and treatment of high blood pressure.
The 2014 guideline offers recommendations for the management of hypertension in:
  • People older or younger than age 60 years
  • People aged ≥18 years with chronic kidney disease
  • People aged ≥18 years with diabetes
  • Black and nonblack populations
2017 ACC/AHA Hypertension Guideline
In 2017 the ACC/AHA and 9 other specialty organizations published an updated hypertension guideline which, among many changes, redefined elevated blood pressure to lower BP levels, enlarging the population considered potential candidates for monitoring and treatment. Learn more here.
2018 ESC/ESH Guideline
In 2018 the ESC/ESH published a guideline which retains the 140/90 threshold definition of hypertension, including for patients with chronic kidney disease (CKD), and emphasizes lifestyle interventions as primary treatment, with consideration of antihypertensive drug therapy only in adults at very high risk, eg with established CVD. In many other respects the 2018 guideline is similar to the 2017 ACC/AHA guideline.